

November 9, 2024

| | |
|--|--|
| To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA | To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 |
|--|--|

Dear Sir / Madam,

Sub: Press Release on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2024.

We enclose a copy of the Press Release on Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2024.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Enclosures: as above.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Press Release

Investor Relations | Corporate Communications
Phone: 040-66721551 | 66725005
Email: ir@aurobindo.com | cc@aurobindo.com

Hyderabad, India, November 09th, 2024: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUOPHARMA) ("Aurobindo") today announced its consolidated financial results for the quarter ended September 30, 2024.

Aurobindo Pharma Limited Q2FY25 Consolidated Financial Results

| Amount (INR Cr) | Q2FY25 | Q2FY24 | % Change YoY | Q1FY25 | % Change QoQ |
|---|--------|--------|--------------|--------|--------------|
| Revenue from Operations | 7,796 | 7,219 | 8.0% | 7,567 | 3.0% |
| EBITDA before R&D | 1,954 | 1,683 | 16.1% | 1,936 | 0.9% |
| EBITDA margin before R&D | 25.1% | 23.3% | 174 bps | 25.6% | -53bps |
| EBITDA before Forex and Other Income | 1,566 | 1,403 | 11.6% | 1,620 | -3.3% |
| EBITDA Margin (%) | 20.1% | 19.4% | 65 bps | 21.4% | -131 bps |
| PBT before share of P/L of JV, Forex, and Exceptional items | 1,193 | 1,105 | 8.0% | 1,324 | -9.9% |
| Net Profit for the period | 817 | 752 | 8.6% | 918 | -11.0% |

Key Highlights of Q2FY25

- Revenue from Operations increased by 8.0% YoY to INR 7,796 Cr with growth across the businesses
- US formulations (excluding Puerto Rico) revenue increased by 4.3% YoY to INR 3,530 Cr (USD 421 million)
- Europe formulations revenue increased by 19.0% YoY to INR 2,105 Cr (EUR 229 million)
- Growth Markets revenue increased by 44.0% YoY to INR 812 Cr (USD 97 million)
- ARV revenue decreased by 22.8% YoY to INR 193 Cr (USD 23 million)
- API revenue remained flat YoY at INR 1,156 Cr (USD 138 million)
- EBITDA before R&D stood at INR 1,954 crores with a margin of 25.1%
- EBITDA before Forex and Other Income stood at INR 1,566 Cr; EBITDA margin at 20.1%
- Research & Development (R&D including depreciation) spend was INR 410 Cr, 5.3% of revenues
- Received final approval for 8 ANDAs including from the USFDA
- Net Profit for the period stood at INR 817 Cr, vs. INR 752 Cr in Q2FY24
- Basic & Diluted EPS grew by 9.1% YoY to INR 14.00 per share

Commenting on the Company's performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "We are pleased with the continued growth in revenues across our key business areas this quarter, reflecting the resilience of our diversified portfolio. While profitability saw a slight dip, primarily due to the transient nature of certain business activities, our underlying performance remains strong. With a solid foundation and ongoing operational improvements, we are confident of maintaining our growth trajectory and achieving our strategic objectives for the year."


Operational Performance (Consolidated)

| ₹ Cr | Q2FY25 | Q2FY24 | Y-o-Y (%) | Q1FY25 | Q-o-Q (%) |
|---|--------------|--------------|--------------|--------------|-------------|
| USA | 3,530 | 3,385 | 4.3% | 3,555 | -0.7% |
| Europe | 2,105 | 1,769 | 19.0% | 1,982 | 6.2% |
| Growth Markets | 812 | 564 | 44.0% | 709 | 14.4% |
| ARV | 193 | 250 | -22.8% | 229 | -15.6% |
| Total Formulations | 6,640 | 5,968 | 11.3% | 6,475 | 2.5% |
| Beta-lactam | 837 | 816 | 2.5% | 791 | 5.9% |
| Non Beta-lactam | 319 | 350 | -8.9% | 301 | 5.9% |
| Total API | 1,156 | 1,166 | -0.9% | 1,092 | 5.9% |
| Consolidated Sales (Ex- Puerto Rico) | 7,796 | 7,134 | 9.3% | 7,567 | 3.0% |
| Puerto Rico | - | 85 | - | - | - |
| Revenue from operations | 7,796 | 7,219 | 8.0% | 7,567 | 3.0% |

*includes domestic formulation sales of INR 71 Cr in Q2FY25

Q2FY25: Consolidated Revenue Breakup - Geography & Business wise

Q2FY25



Q2FY25 Performance

Formulations revenue increased by 11.3% YoY to INR 6,640 Cr

US Formulations

- US revenue increased by 4.3% YoY to INR 3,530 Cr and accounted for 45.3% of consolidated revenue
- In USD terms, revenue increased by 2.9% YoY to USD 421 million
- Filed 10 ANDAs with USFDA during the quarter
- Received final approval for 8 ANDAs during the quarter
- As on 30th September 2024, on a cumulative basis, the company has filed 848 ANDAs with USFDA and received 676 final approvals and 26 tentative approvals
- The company has launched 14 products during the quarter

Europe Formulations

- Europe revenue increased by 19.0% YoY to INR 2,105 Cr and accounted for 27.0% of consolidated revenue
- In Euro terms, revenue increased by 16.3% YoY to EUR 229 million

Growth Markets Formulations

- Growth Markets formulations revenue increased by 44.0% YoY to INR 812 Cr and accounted for 10.4% of consolidated revenue
- In USD terms, revenue increased by 42.3% YoY to USD 97 million
- Domestic formulation sales for the quarter stood at INR 71 Cr

ARV Formulations

- ARV business revenue decreased by 22.8% YoY to INR 193 Cr and accounted for 2.5% of consolidated revenue
- In USD terms, revenue decreased by 23.8% YoY to USD 23 million

Active Pharmaceutical Ingredients (API)

- API business revenue remained flat Y-o-Y at INR 1,156 Cr and contributed 14.8% of consolidated revenue
- In USD terms, revenue declined by 2.2% to USD 138 million

Global Regulatory Filings

| Details | Q2FY25 | Cumulative Filings as on 30 th Sep 2024 |
|---|--------|--|
| US ANDAs (including filings from Aurobindo USA) | 10 | 848 |
| US DMFs (including filings from Eugia and Auro Peptides) | 2 | 294 |
| Formulations Dossiers in other key advanced markets (incl. multiple registrations in Europe, South Africa and Canada) | 38 | 4,499 |
| API filings in other key regulated markets (incl. multiple registrations) | 49 | 3,884 |

Final USFDA Approvals Received in Q2FY25

Received by Aurobindo Pharma Limited

| # | Product | Strength | Therapy area |
|---|---|--|------------------------------|
| 1 | Dutasteride and Tamsulosin Hydrochloride Capsules | 0.5 mg and 0.4 mg | Genitourinary Drugs |
| 2 | Levothyroxine Sodium Tablets USP | 0.137 mg, 0.15 mg, 0.175 mg, 0.2 mg and 0.3 mg | Thyroid Hormones |
| 3 | Estradiol Vaginal Inserts USP | 10 mcg | Hormonal Drug |
| 4 | Posaconazole Delayed Release Tablets | 100 mg | Antifungal Agent |
| 5 | Baricitinib Tablets (FTF) | 1 mg and 2 mg | Pain Relief Drugs |
| 6 | Mycophenolate Mofetil for Oral Suspension USP | 200 mg/mL | Immunosuppressive Agents |
| 7 | Cephalexin Tablets USP | 250 mg and 500 mg | Anti-Infective |
| 8 | Doxepin Tablet | 3 mg and 6 mg | Central Nervous System Drugs |

Q2FY25 Earnings Call Details

The company will host earnings call at **8.30 AM IST on 11th November 2024**, to discuss the performance and answer any questions from participants.

To join the call through Zoom, please pre-register using the link: <http://bit.ly/3AzoIMv>

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 29 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

For further information, please contact:

Investor Relations | Corporate Communications
Phone: 040-66721551 | 66725005
Email: ir@aurobindo.com | cc@aurobindo.com